x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:20:36

Create Medicines' platform allows it to program CARs...

BiotechTV - News ·

2025/12/12

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.

en-us

00:13:44

The leaders of London based LabGenius Therapeutics...

BiotechTV - News ·

2025/12/11

CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.

en-us

00:14:56

Bay Area based Medra, which is building a robotics...

BiotechTV - News ·

2025/12/11

Founder and CEO Michelle Lee highlights the key distinction between Medra and other automated lab equipment, which is that Medra's platform is designed to sense and understand its environment and use that knowledge to make its own intelligent decisions.

en-us

00:18:51

Kymera Therapeutics' Founder & CEO Nello Mainolfi...

BiotechTV - News ·

2025/12/10

He talks about Kymera's dosing methodology, and recaps the data from a degredation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.

en-us

00:19:29

ASH 2025: Kelonia Therapeutics presented convincing...

BiotechTV - News ·

2025/12/09

Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.

en-us

00:10:22

ASH 2025: MaaT Pharma's microbiome based treatment...

BiotechTV - News ·

2025/12/09

Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in the United States.

en-us

00:14:13

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang...

BiotechTV - News ·

2025/12/09

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, and update on global studies of the BCR-ABU/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor.

en-us

00:07:51

ASH 2025: Corvus CEO Richard Miller believes that ITK...

BiotechTV - News ·

2025/12/09

He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighting atopic dermatitis data that will be coming in January.

en-us

00:16:50

ASH 2025: Nurix CEO Arthur Sands discusses his...

BiotechTV - News ·

2025/12/08

He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.

en-us

00:09:52

ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed...

BiotechTV - News ·

2025/12/08

He describes how this asset binds to the extracellular domain and therefore can work for both wild type patients and those with mutations. Plus, recent regulatory news on zipalertinib and when to expect to see autoimmune data.

en-us

00:13:14

ASH 2025: Kura Oncology CEO Troy Wilson discusses the...

BiotechTV - News ·

2025/12/08

He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.

en-us

00:12:48

ASH 2025: Aleta Biotherapeutics' Paul Rennert shares...

BiotechTV - News ·

2025/12/08

He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types.

en-us

00:07:02

ASH 2025: March Biosciences reported 5 complete...

BiotechTV - News ·

2025/12/08

Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.

en-us

00:15:36

Lyell Immunopharma CEO Lynn Seely discusses her...

BiotechTV - News ·

2025/12/08

She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.

en-us

00:10:13

ASH 2025: Rigel's CEO Raul Rodriguez discusses the...

BiotechTV - News ·

2025/12/07

He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.

en-us

00:07:12

ASH 2025: CEO Will West describes how CellCentric is...

BiotechTV - News ·

2025/12/07

Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.

en-us

00:17:45

ASH 2025: Disc Medicine CEO John Quisel walks us...

BiotechTV - News ·

2025/12/07

He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.

en-us

00:12:14

ASH 2025: Orca Bio has an April 6th PDUFA date from...

BiotechTV - News ·

2025/12/07

Co-Founder and CEO Nate Fernhoff walks us through this platform and the clinical data that Orca has previously announced, and new data at ASH. Plus, a journey through the patient experience of how this works.

en-us

00:11:07

ASH 2025: Kite Pharma EVP Cindy Perettie discusses...

BiotechTV - News ·

2025/12/07

She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.

en-us

00:11:32

ASH 2025: Von Willibrand disease is the most common...

BiotechTV - News ·

2025/12/06

Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.

en-us

340 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter